Followers | 918 |
Posts | 48159 |
Boards Moderated | 0 |
Alias Born | 07/22/2008 |
![](https://investorshub.advfn.com/uicon/129869.png?cb=1705717490)
Thursday, September 24, 2020 10:54:58 AM
This could be where SHRG first goes International...Asia, of course.
Holista trades on the Australian Stock Exchange.
![](http://investorshub.advfn.com/uimage/uploads/2020/9/24/euddt0_-_shrg_Holista_CollTech_Bubble_Tea.png)
![](http://investorshub.advfn.com/uimage/uploads/2020/9/24/gfkcz0_-_shrg_Holista_Heng_Fai_Chan.png)
SHRG Beneficial Owners Table
![](http://investorshub.advfn.com/uimage/uploads/2020/9/22/cyqsn0_-_shrg_Ben_Owners_Table_as_of_July_30_2020.png)
SHRG Strong Buy
About Impact BioMedical, Inc.
Impact BioMedical, Inc. (“Impact BioMedical”) is a wholly-owned direct subsidiary of Global BioMedical Pte. Ltd., which in turn is a wholly-owned direct subsidiary of Singapore eDevelopment Limited, a company listed on the Singapore Exchange.
Impact BioMedical strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. By tapping into the scientific expertise of GRDG Sciences, LLC. and Australian Exchange-listed Holista CollTech Limited, Impact BioMedical pledges to undertake a concerted effort in the R&D, drug discovery and development for the prevention, inhibition, and treatment of neurological, oncological and immuno related diseases.
About GRDG Sciences, LLC.
GRDG Sciences, LLC is an advanced research team formed in Florida by natural products discovery drug research scientist, Daryl Thompson. For more information, please visit: www.globalrdg.com.
Link > https://www.pharmavoice.com/newsreleases/impact-biomedical-initiates-quantum-research-program-solve-patent-cliff/
Go to the link above and read the entire PR. It's a little lengthy but worth the read. Look at this...
CORONAVIRUS
Impact, through their strategic partner Global Research and Discovery Group Sciences (“GRDG”), has created a solution called Quantum, a new frontier in pharmaceutical development. Quantum is a new class of medicinal chemistry that uses advanced methods to boost efficacy and persistence of natural compounds and existing drugs while maintaining the safety profile of the original molecules. Instead of modifying functional groups, as is typically done presently in drug discovery, this new technique alters the behavior of molecules at the sub-molecular level. GRDG estimates that 65% of the World Health Organization Essential Medicines List can be improved and re-patented using Quantum. This approach can be used to enhance and patent natural compounds which includes many substances used in traditional medicines around the world.
This research follows the success of GRDG’s recently completed exploratory program to address biomedical threats including the current COVID-19 pandemic which produced the 3F Antimicrobial BioFragrance, the universal therapeutic Linebacker, and the antiviral OTC medication Equivir, which is moving to human clinical trials. These inventions form the core of Impact’s suite of next generation medical technology that was recently valued at approximately US$1.39 Billion by independent experts.
GRDG’s Chief Scientific Advisor is Dr. Roscoe M. Moore, Jr., the former United States Assistant Surgeon General and former Epidemic Intelligence Service Officer at the U.S. Centers for Disease Control and Prevention. Dr. Moore said, “A new direction in drug discovery is sorely needed and Quantum has the potential to revive innovation and development of lifesaving pharmaceuticals.”
GRDG’s Chief Strategy Advisor is Lieutenant Colonel William H. Lyerly Jr., a retired U.S. Army Medical Service Corps Officer, as well as a retired Career Senior Executive / Scientific Professional (ST), with decorated civilian service as a senior official within the U.S. Department of Homeland Security, the U.S. Department of Health and Human Services, the U.S. Agency for International Development, and the U.S. Executive Office of the President (White House). Lieutenant Colonel Lyerly said, “Continued innovation in drug discovery is vital to combat new dangers to human health such as the current COVID-19 pandemic and beyond. Quantum can improve the drug development industry and enable scores of new solutions.”
Impact Biomedical Chairman, Mr. Chan Heng Fai said, “Today, the difficulty in obtaining a pharmaceutical patent and retaining market exclusivity after it expires thwarts the momentum required by pharmaceutical companies to spur greater innovation. Backed by our newly established Quantum solution, we are proud to lead the field by bringing real and cutting-edge solutions to this immense global health challenge. In due time, we believe that Quantum will provide a practical solution for pharmaceutical companies to extend the patent life of their existing drug portfolio, thereby reducing abrupt declines in revenue following the expiration of patents. More importantly, they will be able to focus their resources on developing new, innovative drugs to treat and prevent illnesses for society at-large.”
Daryl Thompson, Director of Scientific Initiatives and founder of GRDG, said, “The patent cliff represents a significant crisis in pharmaceutical innovation. The primary cause of the crisis is that most techniques for modifying natural molecules to pharmaceutical grade products are essentially ‘played out.’
“Another way to explain this is that most of the methods to make drugs have already been published in scientific papers or rationalized in long expired patents. This means that these methods can render the development of new, novel compounds unpatentable. It is essential for a new drug in development qualify for patent protection due to the high costs of bringing a single compound to market. The medium cost of bringing a drug to market today is roughly US$985 million.
Recent SHRG News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 07:53:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 09:05:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 09:40:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:07:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 09:34:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 09:44:20 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 10/30/2023 06:06:12 PM
- Form SEC STAFF ACTION - SEC Staff Action: ORDER • Edgar (US Regulatory) • 10/26/2023 03:00:03 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 10/18/2023 04:51:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2023 12:45:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/22/2023 12:05:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/18/2023 08:00:20 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:30:58 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/10/2023 07:44:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/03/2023 01:00:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2023 09:21:19 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 07/31/2023 09:18:44 PM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM